Loading...
•
Dec 31, 2023
Collegium Q4 2023 Earnings Report
Collegium reported record fourth quarter and full-year 2023 financial results.
Key Takeaways
Collegium Pharmaceutical, Inc. reported a record fourth quarter with net revenue of $149.7 million and a GAAP net income of $31.9 million. The company ended the quarter with $310.5 million in cash, cash equivalents and marketable securities.
Generated record quarterly net revenue of $149.7 million.
Achieved quarterly GAAP Net Income of $31.9 Million.
Delivered record quarterly Adjusted EBITDA of $104.2 Million.
Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million.
Forward Guidance
The Company reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Positive Outlook
- Product Revenues, Net $580.0 to $595.0 million
- Adjusted Operating Expenses (Excluding Stock-Based Compensation) $120.0 to $125.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation) $380.0 to $395.0 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...